NCT05310643View on ClinicalTrials.gov

Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 5, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Nivolumab

"Induction therapy with nivolumab 240 mg; 4 infusions, every 3 weeks.~Maintenance therapy with nivolumab 480 mg; 21 infusions, every 4 weeks."

DRUG

Ipilimumab

Induction therapy with ipilimumab 1 mg/kg; 4 infusions, every 3 weeks.

Trial Locations (9)

Unknown

RECRUITING

CHU Jean Minjoz, Besançon

RECRUITING

Institute Bergonie, Bordeaux

RECRUITING

CHRU Lille, Lille

RECRUITING

CHU Dupuytren, Limoges

RECRUITING

Centre Léon Bérard, Lyon

RECRUITING

ICM Val d'Aurelle, Montpellier

RECRUITING

Centre Antoine Lacassagne, Nice

RECRUITING

Hôpital Saint Antoine, Paris

RECRUITING

CHU Poitiers, Poitiers

All Listed Sponsors
lead

GERCOR - Multidisciplinary Oncology Cooperative Group

OTHER